B. Fall

Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression.

J. Chamberlain, P. Gregorevic, E. Kimura, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.

S. Tapscott, J. Chamberlain, Jay J. Han, 2008, Human molecular genetics.

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy

D. Warnock, S. Shankland, J. Pippin, 2016, PloS one.

Human Molecular Genetics

S. Tapscott, J. Chamberlain, Jay J. Han, 2008 .

Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin

J. Chamberlain, M. Reyes, S. Hauschka, 2005, Gene Therapy.

A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.

J. Faulkner, J. Chamberlain, M. Reyes, 2006, Human molecular genetics.

Incidence of Ichthyophonus hoferi in Puget Sound Fishes and Its Increase with Age of Pacific Herring

K. Stick, J. Winton, P. Hershberger, 2002 .

Li, S, Kimura, E, Fall, BM, Reyes, M, Angello, JC, Welikson, R et al.. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther 12: 1099-1108

J. Chamberlain, M. Reyes, S. Hauschka, 2005 .

Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.

S. Tapscott, Sheng Li, Miki Haraguchi, 2008, Human molecular genetics.

Podocyturia correlates with proteinuria in patients with Fabry disease (FD) and is a potential biomarker of Fabry nephropathy

S. Shankland, J. Pippin, S. Uhrich, 2013 .